<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240215011120
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240215011120" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Thu, 15 Feb 2024 06:11:21 +0000</lastbuilddate>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: miRNAs, Endothelin-1 and Endothelial Glycocalyx Disorders in Shock Severity in Postoperative Cardiac Surgery Patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355252/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):e73. doi: 10.1016/j.jacc.2023.12.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355252/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355252</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.007>10.1016/j.jacc.2023.12.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355252</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Tobias Roeschl</dc:creator>
<dc:creator>Volkmar Falk</dc:creator>
<dc:creator>Felix Schoenrath</dc:creator>
<dc:creator>Alexander Meyer</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: miRNAs, Endothelin-1 and Endothelial Glycocalyx Disorders in Shock Severity in Postoperative Cardiac Surgery Patients</dc:title>
<dc:identifier>pmid:38355252</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.007</dc:identifier>
</item>
<item>
<title>miRNAs, Endothelin-1 and Endothelial Glycocalyx Disorders in Shock Severity in Postoperative Cardiac Surgery Patients</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355251/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):e71. doi: 10.1016/j.jacc.2023.11.034.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355251/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355251</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.034>10.1016/j.jacc.2023.11.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355251</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Salvatore Patanè</dc:creator>
<dc:creator>Roberto Licordari</dc:creator>
<dc:creator>Pietro Venuto</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>miRNAs, Endothelin-1 and Endothelial Glycocalyx Disorders in Shock Severity in Postoperative Cardiac Surgery Patients</dc:title>
<dc:identifier>pmid:38355251</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.034</dc:identifier>
</item>
<item>
<title>Reply: &lt;sup>;18&lt;/sup>;F-Flurpiridaz Myocardial Perfusion PET, What Is it That Matters? Diagnostic or Prognostic Accuracy?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):e69. doi: 10.1016/j.jacc.2023.12.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355250</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.009>10.1016/j.jacc.2023.12.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355250</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jamshid Maddahi</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: &lt;sup>;18&lt;/sup>;F-Flurpiridaz Myocardial Perfusion PET, What Is it That Matters? Diagnostic or Prognostic Accuracy?</dc:title>
<dc:identifier>pmid:38355250</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.009</dc:identifier>
</item>
<item>
<title>&lt;sup>;18&lt;/sup>;F-Flurpiridaz Myocardial Perfusion PET, What Is it That Matters? Diagnostic or Prognostic Accuracy?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355249/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):e67. doi: 10.1016/j.jacc.2023.10.053.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355249/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355249</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.053>10.1016/j.jacc.2023.10.053</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355249</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Federico Caobelli</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>&lt;sup>;18&lt;/sup>;F-Flurpiridaz Myocardial Perfusion PET, What Is it That Matters? Diagnostic or Prognostic Accuracy?</dc:title>
<dc:identifier>pmid:38355249</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.053</dc:identifier>
</item>
<item>
<title>Participation in Competitive Sports by Patients With Congenital Heart Disease: AHA/ACC and EAPC/ESC/AEPC Guidelines Comparison</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>Sports participation in patients with congenital heart disease is an evolving subject. The American Heart Association/American College of Cardiology released a set of guidelines that advise the type and level of sports participation based primarily on anatomical defects with secondary consideration given to hemodynamic effects. Recently, the European Association of Preventive Cardiology/European Society of Cardiology/Association for European Paediatric and Congenital Cardiology offered a...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):772-782. doi: 10.1016/j.jacc.2023.10.037.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Sports participation in patients with congenital heart disease is an evolving subject. The American Heart Association/American College of Cardiology released a set of guidelines that advise the type and level of sports participation based primarily on anatomical defects with secondary consideration given to hemodynamic effects. Recently, the European Association of Preventive Cardiology/European Society of Cardiology/Association for European Paediatric and Congenital Cardiology offered a contrasting approach to sports participation that is based on hemodynamic and electrophysiological profiles of each patient, regardless of anatomical consideration. These guidelines are drastically different in their approaches but do have some similarities. In this review, we compare both documents, focusing on the aim, population, classification of sports, and the methodology of making recommendations. This review aims to assist practicing cardiologists in integrating the available published data and recommendations when counseling patients for sports participation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355248</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.037>10.1016/j.jacc.2023.10.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355248</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Kamel Shibbani</dc:creator>
<dc:creator>Ali Abdulkarim</dc:creator>
<dc:creator>Werner Budts</dc:creator>
<dc:creator>Jolien Roos-Hesselink</dc:creator>
<dc:creator>Jan Müller</dc:creator>
<dc:creator>Keri Shafer</dc:creator>
<dc:creator>Prashob Porayette</dc:creator>
<dc:creator>Ali Zaidi</dc:creator>
<dc:creator>Jacqueline Kreutzer</dc:creator>
<dc:creator>Tarek Alsaied</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Participation in Competitive Sports by Patients With Congenital Heart Disease: AHA/ACC and EAPC/ESC/AEPC Guidelines Comparison</dc:title>
<dc:identifier>pmid:38355248</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.037</dc:identifier>
</item>
<item>
<title>Differences in Circulating Progenitor Cells and Risk of Atherosclerotic Cardiovascular Disease in South Asian Individuals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):770-771. doi: 10.1016/j.jacc.2023.12.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355247</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.020>10.1016/j.jacc.2023.12.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355247</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Aniruddh P Patel</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Differences in Circulating Progenitor Cells and Risk of Atherosclerotic Cardiovascular Disease in South Asian Individuals</dc:title>
<dc:identifier>pmid:38355247</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.020</dc:identifier>
</item>
<item>
<title>Vascular Regenerative Cell Deficiencies in South Asian Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>CONCLUSIONS: South Asian people with cardiometabolic disease had less vascular regenerative and reparative cells suggesting compromised vessel repair capabilities that may contribute to the excess vascular risk in this population. (The Role of South Asian vs European Origins on Circulating Regenerative Cell Exhaustion [ORIGINS-RCE]; NCT05253521).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):755-769. doi: 10.1016/j.jacc.2023.12.012.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: South Asian individuals shoulder a disproportionate burden of cardiometabolic diseases.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to determine if vascular regenerative cell content varies significantly between South Asian and White European people.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Between January 2022 and January 2023, 60 South Asian and 60 White European adults with either documented cardiovascular disease or established diabetes with ≥1 other cardiovascular risk factor were prospectively enrolled. Vascular regenerative cell content in venous blood was enumerated using a flow cytometry assay that is based on high aldehyde dehydrogenase (ALDH<sup>hi</sup>) activity and cell surface marker phenotyping. The primary outcome was the difference in frequency of circulating ALDH<sup>hi</sup> progenitor cells, monocytes, and granulocytes between the 2 groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with White European participants, those of South Asian ethnicity were younger (69 ± 10 years vs 66 ± 9 years; P &lt; 0.05), had lower weight (88 ± 19 kg vs 75 ± 13 kg; P &lt; 0.001), and exhibited a greater prevalence of type 2 diabetes (62% vs 92%). South Asian individuals had markedly lower circulating frequencies of pro-angiogenic ALDH<sup>hi</sup>SSC<sup>low</sup>CD133<sup>+</sup> progenitor cells (P &lt; 0.001) and ALDH<sup>hi</sup>SSC<sup>mid</sup>CD14<sup>+</sup>CD163<sup>+</sup> monocytes with vessel-reparative capacity (P &lt; 0.001), as well as proportionally more ALDH<sup>hi</sup> progenitor cells with high reactive oxygen species content (P &lt; 0.05). After correction for sex, age, body mass index, and glycated hemoglobin, South Asian ethnicity was independently associated with lower ALDH<sup>hi</sup>SSC<sup>low</sup>CD133<sup>+</sup> cell count.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: South Asian people with cardiometabolic disease had less vascular regenerative and reparative cells suggesting compromised vessel repair capabilities that may contribute to the excess vascular risk in this population. (The Role of South Asian vs European Origins on Circulating Regenerative Cell Exhaustion [ORIGINS-RCE]; NCT05253521).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355246</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.012>10.1016/j.jacc.2023.12.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355246</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Aishwarya Krishnaraj</dc:creator>
<dc:creator>Ehab Bakbak</dc:creator>
<dc:creator>Hwee Teoh</dc:creator>
<dc:creator>Yi Pan</dc:creator>
<dc:creator>Irene N Firoz</dc:creator>
<dc:creator>Arjun K Pandey</dc:creator>
<dc:creator>Daniella C Terenzi</dc:creator>
<dc:creator>Raj Verma</dc:creator>
<dc:creator>Basel Bari</dc:creator>
<dc:creator>Asaad I Bakbak</dc:creator>
<dc:creator>Shakkeela Padanilathu Kunjummar</dc:creator>
<dc:creator>Bobby Yanagawa</dc:creator>
<dc:creator>Kim A Connelly</dc:creator>
<dc:creator>C David Mazer</dc:creator>
<dc:creator>Ori D Rotstein</dc:creator>
<dc:creator>Adrian Quan</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Darren K McGuire</dc:creator>
<dc:creator>David A Hess</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Vascular Regenerative Cell Deficiencies in South Asian Adults</dc:title>
<dc:identifier>pmid:38355246</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.012</dc:identifier>
</item>
<item>
<title>Getting to the Heart of the Problem in Spinal Cord Injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):752-754. doi: 10.1016/j.jacc.2023.12.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355245</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.011>10.1016/j.jacc.2023.12.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355245</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Christopher R West</dc:creator>
<dc:creator>Jacquelyn J Cragg</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Getting to the Heart of the Problem in Spinal Cord Injury</dc:title>
<dc:identifier>pmid:38355245</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.011</dc:identifier>
</item>
<item>
<title>Increased Risk of Myocardial Infarction, Heart Failure, and Atrial Fibrillation After Spinal Cord Injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355244/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>CONCLUSIONS: SCI survivors at all levels were at significantly greater risk for heart disease than non-SCI controls, particularly those with severe disability. Clinicians must be aware of the importance of heart disease in SCI survivors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):741-751. doi: 10.1016/j.jacc.2023.12.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart diseases are a growing concern for the spinal cord injury (SCI) population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to compare the incidence of heart diseases between SCI survivors and the general non-SCI population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We identified 5,083 SCI survivors and 1:3 age- and sex-matched non-SCI controls. Study outcomes were myocardial infarction (MI), heart failure (HF), and atrial fibrillation (AF). The cohort was followed up from the index date (diagnosis date for SCI or corresponding date for matched controls) until 2019.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SCI survivors showed a higher risk for MI (adjusted HR [aHR]: 2.41; 95% CI: 1.93-3.00), HF (aHR: 2.24; 95% CI: 1.95-2.56), and AF (aHR: 1.84; 95% CI: 1.49-2.28) compared to controls. The risks were further increased for those who were registered in the National Disability Registry within 1 year from the index date (SCI survivors with disability): SCI survivors with severe disability had the highest risks of MI (aHR: 3.74; 95% CI: 2.43-5.76), HF (aHR: 3.96; 95% CI: 3.05-5.14), and AF (aHR: 3.32; 95% CI: 2.18-5.05). Cervical and lumbar SCI survivors had an increased risk of heart disease regardless of disability compared to matched controls; these risks were slightly higher in those with disability. Thoracic SCI survivors with disability had significantly increased risk of heart disease compared to matched controls.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SCI survivors at all levels were at significantly greater risk for heart disease than non-SCI controls, particularly those with severe disability. Clinicians must be aware of the importance of heart disease in SCI survivors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355244/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355244</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.010>10.1016/j.jacc.2023.12.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355244</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jung Eun Yoo</dc:creator>
<dc:creator>Miso Kim</dc:creator>
<dc:creator>Bongseong Kim</dc:creator>
<dc:creator>Heesun Lee</dc:creator>
<dc:creator>Won Hyuk Chang</dc:creator>
<dc:creator>Jeehyun Yoo</dc:creator>
<dc:creator>Kyungdo Han</dc:creator>
<dc:creator>Dong Wook Shin</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Increased Risk of Myocardial Infarction, Heart Failure, and Atrial Fibrillation After Spinal Cord Injury</dc:title>
<dc:identifier>pmid:38355244</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.010</dc:identifier>
</item>
<item>
<title>Turning to "Omics" in Understanding Fontan-Associated Liver Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):739-740. doi: 10.1016/j.jacc.2023.12.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355243</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.025>10.1016/j.jacc.2023.12.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355243</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Yuli Y Kim</dc:creator>
<dc:creator>Maarouf A Hoteit</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Turning to "Omics" in Understanding Fontan-Associated Liver Disease</dc:title>
<dc:identifier>pmid:38355243</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.025</dc:identifier>
</item>
<item>
<title>Intrahepatic Transcriptomics Differentiate Advanced Fibrosis and Clinical Outcomes in Adults With Fontan Circulation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355242/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>CONCLUSIONS: Patients with FALD and advanced fibrosis or the CCO exhibited upregulated genes related to inflammation, congestion, and angiogenesis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):726-738. doi: 10.1016/j.jacc.2023.12.005.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The molecular mechanisms underlying Fontan-associated liver disease (FALD) remain largely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to assess intrahepatic transcriptomic differences among patients with FALD according to the degree of liver fibrosis and clinical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This retrospective cohort study included adults with the Fontan circulation. Baseline clinical, laboratory, imaging, and hemodynamic data as well as a composite clinical outcome (CCO) were extracted from medical records. Patients were classified into early or advanced fibrosis. RNA was isolated from formalin-fixed paraffin-embedded liver biopsy samples; RNA libraries were constructed with the use of an rRNA depletion method and sequenced on an Illumina Novaseq 6000. Differential gene expression and gene ontology analyses were performed with the use of DESeq2 and Metascape.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 106 patients (48% male, median age 31 years [IQR: 11.3 years]) were included. Those with advanced fibrosis had higher B-type natriuretic peptide levels and Fontan, mean pulmonary artery, and capillary wedge pressures. The CCO was present in 23 patients (22%) and was not predicted by advanced liver fibrosis, right ventricular morphology, presence of aortopulmonary collaterals, or Fontan pressures on multivariable analysis. Samples with advanced fibrosis had 228 upregulated genes compared with early fibrosis. Samples with the CCO had 894 upregulated genes compared with those without the CCO. A total of 136 upregulated genes were identified in both comparisons and were enriched in cellular response to cytokine stimulus or oxidative stress, VEGFA-VEGFR2 signaling pathway, TGF-β signaling pathway, and vasculature development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with FALD and advanced fibrosis or the CCO exhibited upregulated genes related to inflammation, congestion, and angiogenesis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355242/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355242</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.005>10.1016/j.jacc.2023.12.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355242</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Katia Bravo-Jaimes</dc:creator>
<dc:creator>Xiuju Wu</dc:creator>
<dc:creator>Leigh C Reardon</dc:creator>
<dc:creator>Gentian Lluri</dc:creator>
<dc:creator>Jeannette P Lin</dc:creator>
<dc:creator>Jeremy P Moore</dc:creator>
<dc:creator>Glen van Arsdell</dc:creator>
<dc:creator>Reshma Biniwale</dc:creator>
<dc:creator>Ming-Sing Si</dc:creator>
<dc:creator>Bita V Naini</dc:creator>
<dc:creator>Robert Venick</dc:creator>
<dc:creator>Sammy Saab</dc:creator>
<dc:creator>Christopher L Wray</dc:creator>
<dc:creator>Reid Ponder</dc:creator>
<dc:creator>Carl Rosenthal</dc:creator>
<dc:creator>Alexandra Klomhaus</dc:creator>
<dc:creator>Kristina I Böstrom</dc:creator>
<dc:creator>Jamil A Aboulhosn</dc:creator>
<dc:creator>Fady M Kaldas</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Intrahepatic Transcriptomics Differentiate Advanced Fibrosis and Clinical Outcomes in Adults With Fontan Circulation</dc:title>
<dc:identifier>pmid:38355242</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.005</dc:identifier>
</item>
<item>
<title>Salt Intake: Reduce or Substitute?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355241/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):723-725. doi: 10.1016/j.jacc.2023.12.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355241/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355241</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.026>10.1016/j.jacc.2023.12.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355241</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Rik H G Olde Engberink</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Salt Intake: Reduce or Substitute?</dc:title>
<dc:identifier>pmid:38355241</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.026</dc:identifier>
</item>
<item>
<title>Effect of a Salt Substitute on Incidence of Hypertension and Hypotension Among Normotensive Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38355240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>CONCLUSIONS: In Chinese older adults with normal blood pressure, replacing usual salt with a salt substitute may reduce the incidence of hypertension without increasing hypotension episodes. This suggests a desirable strategy for population-wide prevention and control of hypertension and cardiovascular disease, deserving further consideration in future studies. (Diet Exercise and Cardiovascular Health [DECIDE]-Salt Reduction Strategies for the Elderly in Nursing Homes in China [DECIDE-Salt];...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Feb 20;83(7):711-722. doi: 10.1016/j.jacc.2023.12.013.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Reports on the effects of salt substitution among individuals with normal blood pressure are scarce and controversial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to assess the effects of a salt substitute (62.5% NaCl, 25% KCl, and 12.5% flavorings) on incidence of hypertension and hypotension among older adults with normal blood pressure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHOD: A post hoc analysis was conducted among older adults with normal blood pressure participating in DECIDE-Salt, a large, multicenter, cluster-randomized trial in 48 elderly care facilities for 2 years. We used the frailty survival model to compare risk of incident hypertension and the generalized linear mixed model to compare risk of hypotension episodes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with usual salt group (n = 298), the salt substitute group (n = 313) had a lower hypertension incidence (11.7 vs 24.3 per 100 person-years; adjusted HR: 0.60; 95% CI: 0.39 to 0.92; P = 0.02) but did not increase incidence of hypotension episodes (9.0 vs 9.7 per 100 person-years; P = 0.76). Mean systolic/diastolic blood pressure did not increase from the baseline to the end of intervention in the salt substitute group (mean changes: -0.3 ± 11.9/0.2 ± 7.1 mm Hg) but increased in the usual salt group (7.0 ± 14.3/2.1 ± 7.5 mm Hg), resulting in a net reduction of -8.0 mm Hg (95% CI: -12.4 to -3.7 mm Hg) in systolic and -2.0 mm Hg (95% CI: -4.1 to 0.1 mm Hg) in diastolic blood pressure between intervention groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In Chinese older adults with normal blood pressure, replacing usual salt with a salt substitute may reduce the incidence of hypertension without increasing hypotension episodes. This suggests a desirable strategy for population-wide prevention and control of hypertension and cardiovascular disease, deserving further consideration in future studies. (Diet Exercise and Cardiovascular Health [DECIDE]-Salt Reduction Strategies for the Elderly in Nursing Homes in China [DECIDE-Salt]; NCT03290716).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38355240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38355240</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.013>10.1016/j.jacc.2023.12.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38355240</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Xianghui Zhang</dc:creator>
<dc:creator>Yifang Yuan</dc:creator>
<dc:creator>Chenglong Li</dc:creator>
<dc:creator>Xiangxian Feng</dc:creator>
<dc:creator>Hongxia Wang</dc:creator>
<dc:creator>Qianku Qiao</dc:creator>
<dc:creator>Ruijuan Zhang</dc:creator>
<dc:creator>Aoming Jin</dc:creator>
<dc:creator>Jiayu Li</dc:creator>
<dc:creator>Huijuan Li</dc:creator>
<dc:creator>Yangfeng Wu</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of a Salt Substitute on Incidence of Hypertension and Hypotension Among Normotensive Adults</dc:title>
<dc:identifier>pmid:38355240</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.013</dc:identifier>
</item>
<item>
<title>Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38353972/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: In this cohort study of individuals with known HoFH, MI was higher in men compared with women yet age at diagnosis and at first ASCVD event were similar. These findings suggest that early diagnosis and treatment are important in attenuating the excessive cardiovascular risk in both sexes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 14. doi: 10.1001/jamacardio.2023.5597. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic condition characterized by extremely increased low-density lipoprotein (LDL) cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). Heterozygous familial hypercholesterolemia (HeFH) is more common than HoFH, and women with HeFH are diagnosed later and undertreated compared to men; it is unknown whether these sex differences also apply to HoFH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate sex differences in age at diagnosis, risk factors, lipid-lowering treatment, and ASCVD morbidity and mortality in patients with HoFH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Sex-specific analyses for this retrospective cohort study were performed using data from the HoFH International Clinical Collaborators (HICC) registry, the largest global dataset of patients with HoFH, spanning 88 institutions across 38 countries. Patients with HoFH who were alive during or after 2010 were eligible for inclusion. Data entry occurred between February 2016 and December 2020. Data were analyzed from June 2022 to June 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Comparison between women and men with HoFH regarding age at diagnosis, presence of risk factors, lipid-lowering treatment, prevalence, and onset and incidence of ASCVD morbidity (myocardial infarction [MI], aortic stenosis, and combined ASCVD outcomes) and mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Data from 389 women and 362 men with HoFH from 38 countries were included. Women and men had similar age at diagnosis (median [IQR], 13 [6-26] years vs 11 [5-27] years, respectively), untreated LDL cholesterol levels (mean [SD], 579 [203] vs 596 [186] mg/dL, respectively), and cardiovascular risk factor prevalence, except smoking (38 of 266 women [14.3%] vs 59 of 217 men [27.2%], respectively). Prevalence of MI was lower in women (31 of 389 [8.0%]) than men (59 of 362 [16.3%]), but age at first MI was similar (mean [SD], 39 [13] years in women vs 38 [13] years in men). Treated LDL cholesterol levels and lipid-lowering therapy were similar in both sexes, in particular statins (248 of 276 women [89.9%] vs 235 of 258 men [91.1%]) and lipoprotein apheresis (115 of 317 women [36.3%] vs 118 of 304 men [38.8%]). Sixteen years after HoFH diagnosis, women had statistically significant lower cumulative incidence of MI (5.0% in women vs 13.7% in men; subdistribution hazard ratio [SHR], 0.37; 95% CI, 0.21-0.66) and nonsignificantly lower all-cause mortality (3.0% in women vs 4.1% in men; HR, 0.76; 95% CI, 0.40-1.45) and cardiovascular mortality (2.6% in women vs 4.1% in men; SHR, 0.87; 95% CI, 0.44-1.75).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cohort study of individuals with known HoFH, MI was higher in men compared with women yet age at diagnosis and at first ASCVD event were similar. These findings suggest that early diagnosis and treatment are important in attenuating the excessive cardiovascular risk in both sexes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38353972/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38353972</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5597>10.1001/jamacardio.2023.5597</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38353972</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Janneke W C M Mulder</dc:creator>
<dc:creator>Tycho R Tromp</dc:creator>
<dc:creator>Mutaz Al-Khnifsawi</dc:creator>
<dc:creator>Dirk J Blom</dc:creator>
<dc:creator>Krysztof Chlebus</dc:creator>
<dc:creator>Marina Cuchel</dc:creator>
<dc:creator>Laura D'Erasmo</dc:creator>
<dc:creator>Antonio Gallo</dc:creator>
<dc:creator>G Kees Hovingh</dc:creator>
<dc:creator>Ngoc Thanh Kim</dc:creator>
<dc:creator>Jiang Long</dc:creator>
<dc:creator>Frederick J Raal</dc:creator>
<dc:creator>Willemijn A M Schonck</dc:creator>
<dc:creator>Handrean Soran</dc:creator>
<dc:creator>Thanh-Huong Truong</dc:creator>
<dc:creator>Eric Boersma</dc:creator>
<dc:creator>Jeanine E Roeters van Lennep</dc:creator>
<dc:creator>Homozygous Familial Hypercholesterolemia International Clinical Collaborators</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia</dc:title>
<dc:identifier>pmid:38353972</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5597</dc:identifier>
</item>
<item>
<title>Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38353970/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: In this study, higher levels of Lp(a) were associated with MACE, MI, and PAD in both primary and secondary prevention populations regardless of baseline hs-CRP value.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 14. doi: 10.1001/jamacardio.2023.5605. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Elevated lipoprotein(a) (Lp[a]) is a putative causal risk factor for atherosclerotic cardiovascular disease (ASCVD). There are conflicting data as to whether Lp(a) may increase cardiovascular risk only in the presence of concomitant inflammation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate whether Lp(a) is associated with cardiovascular risk independent of high-sensitivity C-reactive protein (hs-CRP) in both primary and secondary prevention populations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This cohort study uses data from 3 distinct cohorts, 1 population-based cohort and 2 randomized clinical trials. Participants included individuals from the UK Biobank (data from 2006-2010) without prevalent ASCVD, participants in the FOURIER (TIMI 59) trial (data from 2013-2017) who had baseline Lp(a) and hs-CRP data, and participants in the SAVOR-TIMI 53 trial (data from 2010-2013) who had prevalent ASCVD and baseline values for Lp(a) and hs-CRP. The data analysis took place from November 2022 to November 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Baseline plasma Lp(a), considered either as a continuous variable or dichotomized at 125 nmol/L.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Risk of major adverse cardiovascular events (MACE) (composite of cardiovascular death, myocardial infarction [MI], or ischemic stroke), the individual MACE components, and peripheral artery disease (PAD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 357 220 individuals in the UK Biobank without prevalent ASCVD, 232 699 (65%) had low hs-CRP (&lt;2 mg/L), and 124 521 (35%) had high hs-CRP (≥2 mg/L) values. In a Cox proportional hazard model adjusted for ASCVD risk factors, higher Lp(a) was associated with increased cardiovascular risk regardless of baseline hs-CRP value for MACE (hs-CRP ≥2 mg/L: hazard ratio [HR] per 50-nmol/L higher Lp[a], 1.05; 95% CI, 1.04-1.07; P &lt; .001; for hs-CRP &lt;2 mg/L: HR, 1.05; 95% CI, 1.04-1.07; P &lt; .001; P = .80 for interaction), as well as MI, ischemic stroke, and PAD individually. Among 34 020 individuals in the FOURIER and SAVOR trials with baseline cardiometabolic disease, there were 17 643 (52%) with low and 16 377 (48%) with high baseline hs-CRP values. In Cox proportional hazard models using aggregated data from FOURIER and SAVOR, higher baseline Lp(a) was associated with increased cardiovascular risk regardless of baseline hs-CRP for MACE (hs-CRP ≥2 mg/L: HR per 50-nmol/L higher Lp[a], 1.02; 95% CI, 1.00-1.05; P = .04; hs-CRP &lt;2 mg/L: HR, 1.05; 95% CI, 1.02-1.08; P &lt; .001; P = .16 for interaction), MI, and PAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, higher levels of Lp(a) were associated with MACE, MI, and PAD in both primary and secondary prevention populations regardless of baseline hs-CRP value.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38353970/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38353970</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5605>10.1001/jamacardio.2023.5605</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38353970</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Aeron M Small</dc:creator>
<dc:creator>Ashley Pournamdari</dc:creator>
<dc:creator>Giorgio E M Melloni</dc:creator>
<dc:creator>Benjamin M Scirica</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Itamar Raz</dc:creator>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Robert P Giugliano</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Gina M Peloso</dc:creator>
<dc:creator>Nicholas A Marston</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:date>2024-02-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations</dc:title>
<dc:identifier>pmid:38353970</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5605</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38353752/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Feb 1;9(2):100. doi: 10.1001/jamacardio.2023.3647.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38353752/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38353752</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3647>10.1001/jamacardio.2023.3647</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38353752</guid>
<pubDate>Wed, 14 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:38353752</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3647</dc:identifier>
</item>
<item>
<title>Carbonylation of Runx2 at K176 by 4-Hydroxynonenal Accelerates Vascular Calcification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38348663/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>CONCLUSIONS: Our results suggest that 4-HNE increases Runx2 stabilization by directly carbonylating its K176 site and promotes vascular calcification. ALDH2 might be a potential target for the treatment of vascular calcification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 13. doi: 10.1161/CIRCULATIONAHA.123.065830. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Vascular calcification, which is characterized by calcium deposition in arterial walls and the osteochondrogenic differentiation of vascular smooth muscle cells, is an actively regulated process that involves complex mechanisms. Vascular calcification is associated with increased cardiovascular adverse events. The role of 4-hydroxynonenal (4-HNE), which is the most abundant stable product of lipid peroxidation, in vascular calcification has been poorly investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Serum was collected from patients with chronic kidney disease and controls, and the levels of 4-HNE and 8-iso-prostaglandin F2α were measured. Sections of coronary atherosclerotic plaques from donors were immunostained to analyze calcium deposition and 4-HNE. A total of 658 patients with coronary artery disease who received coronary computed tomography angiography were recruited to analyze the relationship between coronary calcification and the rs671 mutation in aldehyde dehydrogenase 2 (ALDH2). ALDH2 knockout (ALDH2<sup>-/-</sup>) mice, smooth muscle cell-specific ALDH2 knockout mice, ALDH2 transgenic mice, and their controls were used to establish vascular calcification models. Primary mouse aortic smooth muscle cells and human aortic smooth muscle cells were exposed to medium containing β-glycerophosphate and CaCl<sub>2</sub> to investigate cell calcification and the underlying molecular mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Elevated 4-HNE levels were observed in the serum of patients with chronic kidney disease and model mice and were detected in calcified artery sections by immunostaining. ALDH2 knockout or smooth muscle cell-specific ALDH2 knockout accelerated the development of vascular calcification in model mice, whereas overexpression or activation prevented mouse vascular calcification and the osteochondrogenic differentiation of vascular smooth muscle cells. In patients with coronary artery disease, patients with ALDH2 rs671 gene mutation developed more severe coronary calcification. 4-HNE promoted calcification of both mouse aortic smooth muscle cells and human aortic smooth muscle cells and their osteochondrogenic differentiation in vitro. 4-HNE increased the level of Runx2 (runt-related transcription factor-2), and the effect of 4-HNE on promoting vascular smooth muscle cell calcification was ablated when Runx2 was knocked down. Mutation of Runx2 at lysine 176 reduced its carbonylation and eliminated the 4-HNE-induced upregulation of Runx2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results suggest that 4-HNE increases Runx2 stabilization by directly carbonylating its K176 site and promotes vascular calcification. ALDH2 might be a potential target for the treatment of vascular calcification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38348663/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38348663</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065830>10.1161/CIRCULATIONAHA.123.065830</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38348663</guid>
<pubDate>Tue, 13 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Xiaoxuan Zhai</dc:creator>
<dc:creator>Shengchuan Cao</dc:creator>
<dc:creator>Jiali Wang</dc:creator>
<dc:creator>Bao Qiao</dc:creator>
<dc:creator>Xuehao Liu</dc:creator>
<dc:creator>Rui Hua</dc:creator>
<dc:creator>Menglin Zhao</dc:creator>
<dc:creator>Shukun Sun</dc:creator>
<dc:creator>Yu Han</dc:creator>
<dc:creator>Shuo Wu</dc:creator>
<dc:creator>Jiaojiao Pang</dc:creator>
<dc:creator>Qiuhuan Yuan</dc:creator>
<dc:creator>Bailu Wang</dc:creator>
<dc:creator>Feng Xu</dc:creator>
<dc:creator>Shujian Wei</dc:creator>
<dc:creator>Yuguo Chen</dc:creator>
<dc:date>2024-02-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Carbonylation of Runx2 at K176 by 4-Hydroxynonenal Accelerates Vascular Calcification</dc:title>
<dc:identifier>pmid:38348663</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065830</dc:identifier>
</item>
<item>
<title>Molecular and Spatial Signatures of Mouse Embryonic Endothelial Cells at Single-Cell Resolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38348657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>CONCLUSIONS: Our results provide a spatiotemporal map of embryonic EC heterogeneity at single-cell resolution and demonstrate that the diversity of ECs in the embryo arises from both tissue origin and vascular-bed position. Developing aECs and vECs share common venous-featured capillary precursors and are regulated by distinct transcriptional regulatory networks.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 13. doi: 10.1161/CIRCRESAHA.123.323956. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Mature endothelial cells (ECs) are heterogeneous, with subtypes defined by tissue origin and position within the vascular bed (ie, artery, capillary, vein, and lymphatic). How this heterogeneity is established during the development of the vascular system, especially arteriovenous specification of ECs, remains incompletely characterized.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used droplet-based single-cell RNA sequencing and multiplexed error-robust fluorescence in situ hybridization to define EC and EC progenitor subtypes from E9.5, E12.5, and E15.5 mouse embryos. We used trajectory inference to analyze the specification of arterial ECs (aECs) and venous ECs (vECs) from EC progenitors. Network analysis identified candidate transcriptional regulators of arteriovenous differentiation, which we tested by CRISPR loss of function in human-induced pluripotent stem cells undergoing directed differentiation to arterial or vECs (human-induced pluripotent stem cell-aECs or human-induced pluripotent stem cell-vECs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From the single-cell transcriptomes of 7682 E9.5 to E15.5 ECs, we identified 19 EC subtypes, including <i>Etv2</i><sup>+</sup><i>Bnip3</i><sup>+</sup> EC progenitors. Spatial transcriptomic analysis of 15 448 ECs provided orthogonal validation of these EC subtypes and established their spatial distribution. Most embryonic ECs were grouped by their vascular-bed types, while ECs from the brain, heart, liver, and lung were grouped by their tissue origins. Arterial (<i>Eln</i>, <i>Dkk2</i>, <i>Vegfc</i>, and <i>Egfl8</i>), venous (<i>Fam174b</i> and <i>Clec14a</i>), and capillary (<i>Kcne3</i>) marker genes were identified. Compared with aECs, embryonic vECs and capillary ECs shared fewer markers than their adult counterparts. Early capillary ECs with venous characteristics as a branch point for differentiation of aEC and vEC lineages.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results provide a spatiotemporal map of embryonic EC heterogeneity at single-cell resolution and demonstrate that the diversity of ECs in the embryo arises from both tissue origin and vascular-bed position. Developing aECs and vECs share common venous-featured capillary precursors and are regulated by distinct transcriptional regulatory networks.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38348657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38348657</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323956>10.1161/CIRCRESAHA.123.323956</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38348657</guid>
<pubDate>Tue, 13 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jian Chen</dc:creator>
<dc:creator>Xiaoran Zhang</dc:creator>
<dc:creator>Daniel Morris DeLaughter</dc:creator>
<dc:creator>Michael A Trembley</dc:creator>
<dc:creator>Shaila Saifee</dc:creator>
<dc:creator>Feng Xiao</dc:creator>
<dc:creator>Jiehui Chen</dc:creator>
<dc:creator>Pingzhu Zhou</dc:creator>
<dc:creator>Christine E Seidman</dc:creator>
<dc:creator>Jonathan G Seidman</dc:creator>
<dc:creator>William T Pu</dc:creator>
<dc:date>2024-02-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Molecular and Spatial Signatures of Mouse Embryonic Endothelial Cells at Single-Cell Resolution</dc:title>
<dc:identifier>pmid:38348657</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323956</dc:identifier>
</item>
<item>
<title>&lt;em>;N&lt;/em>;-Glycosylation Profiles of Immunoglobulin G and Future Cardiovascular Events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38348651/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>CONCLUSIONS: An IgG N-glycan profile was associated with incident CVD in 2 populations (primary and secondary prevention), involving an agalactosylated glycan associated with increased risk of CVD, while several digalactosylated and sialylated IgG glycans associated with decreased risk. An IgG glycan score was positively associated with future CVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 13. doi: 10.1161/CIRCRESAHA.123.323623. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Posttranslational glycosylation of IgG can modulate its inflammatory capacity through structural variations. We examined the association of baseline IgG N-glycans and an IgG glycan score with incident cardiovascular disease (CVD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: IgG N-glycans were measured in 2 nested CVD case-control studies: JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; NCT00239681, primary prevention; discovery; Npairs=162); and TNT trial (Treating to New Targets; NCT00327691, secondary prevention; validation; Npairs=397). Using conditional logistic regression, we investigated the association of future CVD with baseline IgG N-glycans and a glycan score adjusting for clinical risk factors (statin treatment, age, sex, race, lipids, hypertension, and smoking) in JUPITER. Significant associations were validated in TNT, using a similar model further adjusted for diabetes. Using least absolute shrinkage and selection operator regression, an IgG glycan score was derived in JUPITER as a linear combination of selected IgG N-glycans.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Six IgG N-glycans were associated with CVD in both studies: an agalactosylated glycan (IgG-GP4) was positively associated, while 3 digalactosylated glycans (IgG glycan peaks 12, 13, 14) and 2 monosialylated glycans (IgG glycan peaks 18, 20) were negatively associated with CVD after multiple testing correction (overall false discovery rate &lt;0.05). Four LASSO-selected IgG N-glycans comprised the IgG glycan score, which was associated with CVD in JUPITER (adjusted hazard ratio per glycan score SD, 2.08 [95% CI, 1.52-2.84]) and validated in TNT (adjusted hazard ratio per SD, 1.20 [95% CI, 1.03-1.39]). The area under the curve changed from 0.693 for the model without the score to 0.728 with the score in JUPITER (PLRT=1.1×10<sup>-</sup><sup>6</sup>) and from 0.635 to 0.637 in TNT (PLRT=0.017).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: An IgG N-glycan profile was associated with incident CVD in 2 populations (primary and secondary prevention), involving an agalactosylated glycan associated with increased risk of CVD, while several digalactosylated and sialylated IgG glycans associated with decreased risk. An IgG glycan score was positively associated with future CVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38348651/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38348651</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323623>10.1161/CIRCRESAHA.123.323623</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38348651</guid>
<pubDate>Tue, 13 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Rosangela A Hoshi</dc:creator>
<dc:creator>Branimir Plavša</dc:creator>
<dc:creator>Yanyan Liu</dc:creator>
<dc:creator>Irena Trbojević-Akmačić</dc:creator>
<dc:creator>Robert J Glynn</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Richard D Cummings</dc:creator>
<dc:creator>Ivan Gudelj</dc:creator>
<dc:creator>Gordan Lauc</dc:creator>
<dc:creator>Olga V Demler</dc:creator>
<dc:creator>Samia Mora</dc:creator>
<dc:date>2024-02-13</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>&lt;em>;N&lt;/em>;-Glycosylation Profiles of Immunoglobulin G and Future Cardiovascular Events</dc:title>
<dc:identifier>pmid:38348651</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323623</dc:identifier>
</item>
<item>
<title>Multimodal Imaging Evidence for Optimized Blood Pressure Control Following Hypertensive Pregnancy: Mechanistic Insights Into Beneficial Cardiac Remodeling From the POP-HT Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38346108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 13;149(7):542-544. doi: 10.1161/CIRCULATIONAHA.124.068282. Epub 2024 Feb 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38346108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38346108</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068282>10.1161/CIRCULATIONAHA.124.068282</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38346108</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Kerryn W Reding</dc:creator>
<dc:creator>Jennifer H Jordan</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Multimodal Imaging Evidence for Optimized Blood Pressure Control Following Hypertensive Pregnancy: Mechanistic Insights Into Beneficial Cardiac Remodeling From the POP-HT Trial</dc:title>
<dc:identifier>pmid:38346108</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068282</dc:identifier>
</item>
<item>
<title>The Feminine Face of Heart Disease 2024</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38346107/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240215011120&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Feb 13;149(7):489-491. doi: 10.1161/CIRCULATIONAHA.123.064460. Epub 2024 Feb 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38346107/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240215011120&v=2.18.0">38346107</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064460>10.1161/CIRCULATIONAHA.123.064460</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38346107</guid>
<pubDate>Mon, 12 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Nanette K Wenger</dc:creator>
<dc:date>2024-02-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Feminine Face of Heart Disease 2024</dc:title>
<dc:identifier>pmid:38346107</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064460</dc:identifier>
</item>





























</channel>
</rss>